FDA Criticized for Working Too Closely With Biotech Company to Approve Alzheimer’s Drug
New findings from a congressional investigation into the Food and Drug Administration and the biotech company Biogen find that the FDA broke its own protocols to approve a new Alzheimer’s drug last year. The findings conclude that the regulator worked too closely with Biogen, despite significant concerns over the limited and side effects of the […]
Research Linked to Leading Cause of Alzheimer’s Disease May Have Been Fabricated
For nearly two decades, Alzheimer’s disease research, research funding, and prescribed drugs have been centered around a 2006 research paper hypothesizing that the cognitive decline causing the debilitating disease is due to buildup in the brain of a protein called the amyloid beta (Aβ) protein. But a recent investigation is questioning whether the data in […]
